HK Stock Market Move | FOURSEMI (03625) rose more than 17% to a new high, surpassing the IPO price by more than 1.4 times. The total market value has exceeded HK$10 billion.
Fourier (03625) rose against the market by more than 17%, reaching a high of 96.4 Hong Kong dollars to continue hitting a new high. Compared to the IPO price of 40 Hong Kong dollars, it has risen by over 140%, with a total market value surpassing one billion Hong Kong dollars. As of the time of writing, it has risen by 16.34% to 95.05 Hong Kong dollars, with a trading volume of 39.8943 million Hong Kong dollars.
FOURSEMI (03625) rose more than 17% against the market, hitting a high of 96.4 Hong Kong dollars, continuing to set new records. Compared to the IPO price of 40 Hong Kong dollars, it has risen by more than 140%, and the total market value has also surpassed one billion Hong Kong dollars. As of the time of publication, it rose by 16.34%, reaching 95.05 Hong Kong dollars, with a turnover of 39.8943 million Hong Kong dollars.
Public information shows that FOURSEMI Semiconductor's IPO in Hong Kong was oversubscribed by a staggering 3117 times, with over 110,000 people subscribing, making it one of the most sought-after star stocks in the hard technology sector this year. After a successful listing, FOURSEMI Semiconductor became the first stock of "AI audio chip" in Hong Kong stocks.
Related Articles

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.
China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


